Drugs that contain Ruxolitinib Phosphate

1. Drug name - JAKAFI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(5 years from now)

US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(5 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101448826A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Mar, 2013

(9 years ago)

CN103214484B INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103254190A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103214483B INCYTE CORP Heteroaryl Two Surface Kinase Inhibitor Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine
Dec, 2026

(4 years from now)

CN103214483A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103254190B INCYTE CORP Two Surfaces Of Heteroaryl Janus Kinases Inhibitors Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine
Dec, 2026

(4 years from now)

CN103214484A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103524509B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

IN269841B INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

IN200802365P2 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3070090B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Aug, 2021

(1 year, 1 month ago)

EP3070090A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Aug, 2021

(1 year, 1 month ago)

EP2474545A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2474545B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343298A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2348023B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2348023A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3184526A1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP3466953B1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP2343298B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2426129B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3184526B1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP3466953A1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP2348023B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2426129A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343298B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2455382B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2455382A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP1966202A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP1966202B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP2173752B2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B1 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752A2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731B1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731A1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814722 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec, 2026

(4 years from now)

US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

US8829013 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US10016429 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For the treatment of polycythemia vera; for the treatment of intermediate or high-risk myelofibrosis; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

2. Drug name - OPZELURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(5 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(5 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101448826A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Mar, 2013

(9 years ago)

CN103214484B INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103254190A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103214483B INCYTE CORP Heteroaryl Two Surface Kinase Inhibitor Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine
Dec, 2026

(4 years from now)

CN103214483A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103254190B INCYTE CORP Two Surfaces Of Heteroaryl Janus Kinases Inhibitors Substituted Pyrrolo [2 3-B] Pyridine And Pyrrolo [2 3-B] Pyrimidine
Dec, 2026

(4 years from now)

CN103214484A INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

CN103524509B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN103524509A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582B INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

CN101932582A INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

IN269841B INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

IN200802365P2 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3070090B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Aug, 2021

(1 year, 1 month ago)

EP3070090A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Aug, 2021

(1 year, 1 month ago)

EP2474545A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2474545B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343298A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2348023B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2348023A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3184526A1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP3466953B1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP2343298B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2426129B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299B9 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP3184526B1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP3466953A1 INCYTE CORP Pyrrolo[2,3-D]Pyrimidine Derivative As Janus Kinase Inhibitor
Dec, 2026

(4 years from now)

EP2348023B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2426129A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343299A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2343298B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2455382B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP2455382A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Dec, 2026

(4 years from now)

EP1966202A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP1966202B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP2173752B2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752B1 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2173752A2 INCYTE CORP Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731B1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP2740731A1 INCYTE CORP Crystalline Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369A1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

EP3495369B1 INCYTE CORP Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639310 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

US9974790 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec, 2026

(4 years from now)

US10610530 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun, 2028

(5 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

US10758543 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 1.5% BASE CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.